Interferon-free, direct-acting antiviral therapy for chronic hepatitis C
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Interferon-free, direct-acting antiviral therapy for chronic hepatitis C
Authors
Keywords
-
Journal
JOURNAL OF VIRAL HEPATITIS
Volume 22, Issue 11, Pages 861-870
Publisher
Wiley
Online
2015-06-17
DOI
10.1111/jvh.12422
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Analysis of the hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938
- (2014) Jeremie Guedj et al. ANTIVIRAL THERAPY
- ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection
- (2014) Pietro Andreone et al. GASTROENTEROLOGY
- O58 RESULTS FROM THE PHASE 2 PEARL-I STUDY: INTERFERON-FREE REGIMENS OF ABT-450/R + ABT-267 WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HCV GENOTYPE 4 INFECTION
- (2014) C. Hezode et al. JOURNAL OF HEPATOLOGY
- P1300 EFFICACY AND SAFETY OF DACLATASVIR IN COMBINATION WITH ASUNAPREVIR (DCV+ASV) IN CIRRHOTIC AND NON-CIRRHOTIC PATIENTS WITH HCV GENOTYPE 1B: RESULTS OF THE HALLMARK DUAL STUDY
- (2014) J.-H. Kao et al. JOURNAL OF HEPATOLOGY
- P1299 PEARL-III: 12 WEEKS OF ABT-450/R/267 + ABT-333 ACHIEVED SVR IN >99% OF 419 TREATMENT-NAIVE HCV GENOTYPE 1B-INFECTED ADULTS WITH OR WITHOUT RIBAVIRIN
- (2014) P. Ferenci et al. JOURNAL OF HEPATOLOGY
- Discovery of ABT-267, a Pan-Genotypic Inhibitor of HCV NS5A
- (2014) David A. DeGoey et al. JOURNAL OF MEDICINAL CHEMISTRY
- All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study
- (2014) Michael Manns et al. LANCET
- Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
- (2014) Eric Lawitz et al. LANCET
- An Interferon-free Antiviral Regimen for HCV after Liver Transplantation
- (2014) Paul Y. Kwo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
- (2014) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
- (2014) Jordan J. Feld et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
- (2014) Kris V. Kowdley et al. NEW ENGLAND JOURNAL OF MEDICINE
- ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV
- (2014) Peter Ferenci et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
- (2014) Mark S. Sulkowski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1
- (2014) Kris V. Kowdley et al. NEW ENGLAND JOURNAL OF MEDICINE
- ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
- (2014) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA
- (2014) David B. Ascher et al. Scientific Reports
- Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection
- (2013) Gregory T. Everson et al. GASTROENTEROLOGY
- A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1
- (2013) Eric Lawitz et al. JOURNAL OF HEPATOLOGY
- NS5A inhibitors in the treatment of hepatitis C
- (2013) Jean-Michel Pawlotsky JOURNAL OF HEPATOLOGY
- Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders
- (2013) Anna S. Lok et al. JOURNAL OF HEPATOLOGY
- The changing epidemiology of hepatitis C virus infection in the United States: National health and nutrition examination survey 2001 through 2010
- (2013) Ivo Ditah et al. JOURNAL OF HEPATOLOGY
- Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
- (2013) Eric Lawitz et al. LANCET
- New therapeutic strategies in HCV: polymerase inhibitors
- (2013) Ludmila Gerber et al. LIVER INTERNATIONAL
- Faldaprevir and Deleobuvir for HCV Genotype 1 Infection
- (2013) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C
- (2013) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Maximizing Opportunities and Avoiding Mistakes in Triple Therapy for Hepatitis C Virus
- (2012) A. Sidney Barritt et al. GASTROENTEROLOGY
- A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C
- (2012) Eric J. Lawitz et al. JOURNAL OF HEPATOLOGY
- Novel Therapies for Hepatitis C: Insights from the Structure of the Virus
- (2011) Dahlene N. Fusco et al. Annual Review of Medicine
- Response-guided and -unguided treatment of chronic hepatitis C
- (2011) K. Rajender Reddy et al. LIVER INTERNATIONAL
- Boceprevir for Untreated Chronic HCV Genotype 1 Infection
- (2011) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
- (2011) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action
- (2011) Jan Paeshuyse et al. Current Opinion in Virology
- A Sustained Virologic Response Is Durable in Patients With Chronic Hepatitis C Treated With Peginterferon Alfa-2a and Ribavirin
- (2010) Mark G. Swain et al. GASTROENTEROLOGY
- Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
- (2010) Min Gao et al. NATURE
- Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients
- (2009) Simone Susser et al. HEPATOLOGY
- Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection
- (2009) John G. McHutchison et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now